Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical outcomes and healthcare resource use in triple-class exposed patients with relapsed/refractory multiple myeloma.

Future oncology (London, England)·2025
Same author

Prevalence and Significance of Incidental PET/CT Findings of Cancer Detected in Patients Evaluated for Their Primary Hematologic Malignancy: A Systematic Review.

Current oncology (Toronto, Ont.)·2024
Same author

Doxycycline Plus Bortezomib-Containing Regimens for the Treatment of Light-Chain Amyloidosis in the Frontline Setting: Experience from the Amyloidosis Program of Calgary.

Current oncology (Toronto, Ont.)·2024
Same author

Long-term follow-up of outcomes including progression-free survival 2 in patients with transplant-ineligible multiple myeloma in the real-world practice: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) database.

EJHaem·2024
Same author

ctDNA as an Adjunct to Posttreatment PET for Head and Neck Cancer Recurrence Risk Assessment.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery·2024
Same author

Daratumumab for the treatment of relapsed/refractory AL amyloidosis: experience from the amyloidosis Program of Calgary (APC).

Leukemia & lymphoma·2023

Related Experiment Video

Updated: Sep 10, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

BCMA CAR-T: From Multiple Myeloma to Light-Chain Amyloidosis.

Ellen Lewis1,2, Victor Hugo Jimenez-Zepeda1,2,3

  • 1Arthur Child Comprehensive Cancer Centre, Calgary, AB T2N 4N2, Canada.

Current Oncology (Toronto, Ont.)
|August 27, 2025
PubMed
Summary

B-cell maturation antigen (BCMA) therapies show promise for relapsed/refractory light-chain (AL) amyloidosis. This review examines BCMA-directed treatments, including CAR-T cell therapy, comparing their efficacy and tolerability to multiple myeloma outcomes.

Keywords:
BCMABCMA CAR-Tlight-chain amyloidosismultiple myeloma

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

791
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K

Related Experiment Videos

Last Updated: Sep 10, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

791
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Light-chain (AL) amyloidosis is a rare, life-threatening plasma cell disorder.
  • Organ damage and mortality risk are high without treatment.
  • Optimal strategies for relapsed/refractory (RR) AL amyloidosis are lacking, with no FDA-approved therapies.

Purpose of the Study:

  • To review the efficacy and tolerability of B-cell maturation antigen (BCMA)-directed therapies in AL amyloidosis.
  • To emphasize CAR-T cell therapy within BCMA-directed treatments.
  • To compare outcomes in AL amyloidosis with those in relapsed/refractory multiple myeloma (RRMM).

Main Methods:

  • Literature review of BCMA-directed therapies in AL amyloidosis.
  • Focus on CAR-T cell therapy, antibody-drug conjugates, and bispecific antibodies.
  • Comparative analysis with existing RRMM treatment data.

Main Results:

  • BCMA-targeted therapies are emerging as a potential treatment avenue for RR AL amyloidosis.
  • CAR-T cell therapy demonstrates potential, with ongoing research into its application.
  • Data from RRMM provide a benchmark for evaluating BCMA-directed therapy efficacy in AL amyloidosis.

Conclusions:

  • BCMA-directed therapies, particularly CAR-T cell therapy, represent a promising frontier for managing RR AL amyloidosis.
  • Further research is crucial to establish optimal treatment protocols and expand therapeutic options.
  • Translating successes from RRMM offers valuable insights for AL amyloidosis treatment development.